MedTrace Logo

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

NCT03804671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-07-25

Study results available
· View outcomes & findings →

Summary

To investigate the absolute oral bioavailability of BI 730357 administered as tablet compared with \[C-14\]BI 730357 BS administered as intravenous microtracer

Conditions

  • Healthy

Interventions

DRUG

BI 730357

Oral dose

DRUG

BI 730357 mixed with [C-14] BI 730357 BS

Intravenous dose

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-03-26
Completion
2019-03-26

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03804671 on ClinicalTrials.gov